🔗 Share this article

Given that the United States proceeds with sweeping revisions to its vaccination guidelines, one figure has emerged in a surprising turn: Høeg, a Danish American physician and public health researcher who rose to prominence by casting doubt on Covid shots throughout the pandemic and has focused upon potential deaths after COVID-19 immunization in her recent tenure at the Food and Drug Administration.

Planned Changes to Pediatric Immunization Schedule

Health officials had intended to unveil sweeping changes to the childhood immunization program earlier this month, bringing the US with the Danish immunization schedule, sources say – a substantial departure that would put the US out of step with much of the global community with no evidence for public health gain. The announcement has been pushed back until the next year.

Rather than Vinay Prasad, Tracy Beth Høeg is listed to speak at the event. She was recently named temporary leader of the FDA’s drug evaluation center, the fifth individual to run the division this year.

Consolidating Power at the Regulatory Body

This interim role could signify a tighter collaboration between the pharmaceutical and biologics divisions as Dr. Høeg and Prasad consolidate power at the FDA – and it signals a greater focus upon dismantling long-standing vaccines at the FDA.

Dr. Høeg has repeatedly called for halting specific childhood shot schedules in the US in order to be more in line with the Danish model, a society with universal health coverage and a number of inhabitants roughly the size of Wisconsin’s.

So far public appearances, she has kept her attention on vaccines – traditionally the domain of Prasad, director of the FDA’s Center for Biologics Evaluation and Research (CBER) – as opposed to medication approval.

Doubts Over Expertise

Dr. Høeg has little discernible experience in drug development, regulation or administrative roles, which has been typical for previous heads of the Center for Biologics Evaluation and Research. She has been employed at the FDA as a senior adviser to the FDA chief and CBER since March.

“It seems she lacks to have the necessary background” for running the CDER, remarked Jonathan Howard. “She lacks experience running a randomized controlled trial. She has no expertise in running a sizeable institution. She lacks background in pharmaceutical oversight.”

Past directors of the center would “grasp legal statutes and the research of medication creation”, said a former acting FDA commissioner. “Clearly, she has not acquired the type of experience that previous people who ran CBER have had.”

This division has an enormous portfolio at the agency, she stated.

“Many people just zeroes in on the novel medication approvals, but the generic drug division approves thousands of generic medications. There’s a biosimilars division, over-the-counter program and so forth, and all of those need to be looked after,” she noted. “The area you overlook, that is precisely what that I always told people is going to come back to haunt you.”

Additionally, a major management aspect to the role, which manages in excess of 5,000 staff members. “It’s a enormous management job, if you execute it properly,” the former official said.

Response and Disputed Policies

When asked about questions about Dr. Høeg's fitness for the role and whether this selection signifies more teamwork among FDA leaders on immunizations, a press secretary said that the “concerns rely on incorrect presumptions”.

“Her experience aligns with the functions of her position,” the official stated, noting the months Høeg spent counseling the agency head on “medication safety and oversight research, including predictive safety algorithms and shot safety tracking”.

As the temporary head, Høeg inherits the agency head's controversial fast-track approval initiative, a contentious expedited medication authorization process that apparently worried her former heads. “By what process are these drugs being chosen for this voucher program? Who takes the decisions?” Dr. Howard questioned. “There is a lot of lack of transparency happening at the agency right now.”

Overall, he remarked, “the agency seems to be moving towards less stringent rules of all drugs, except for immunizations.”

Established Track Record on Vaccines

Regarding immunizations, Dr. Høeg has a more documented, if problematic, past, some experts have noted. She published a research paper using unconfirmed volunteer-provided data to assess the incidence of myocarditis following Covid vaccination. She advised the Florida surgeon general Joseph Ladapo, who was said to have changed statistics to suggest Covid vaccinations are riskier than they are.

Included in her “desired changes” for the new administration included revising regulations for new vaccines and discontinuing “optional” vaccines, she said post-election on a audio program. At the FDA, Høeg has reportedly proposed barring teenage boys from receiving Covid vaccines.

“She’s an thorough true believer who starts off with her beliefs and works backwards to accommodate the evidence in a extremely disingenuous, dishonest way,” Howard said.

Taking Control and a “Campaign of Retribution”

Dr. Høeg aligned with other contrarians, {like|